New peptide injection could get athletes back in the game faster
NCT ID NCT07437547
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tests whether a daily injection of BPC 157, a synthetic peptide, can help people with a moderate hamstring tear heal faster. 120 adults aged 18-45 with a recent MRI-confirmed grade II strain will receive either BPC 157 or a placebo for 14 days, plus standard rehab. The main goals are to see how quickly they can return to sport and how much the muscle injury shrinks on MRI.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BPC 157 (a synthetic peptide given as a daily injection for 14 days)
What this could lead to
If it works, this could provide a new treatment to help athletes and active people recover faster from hamstring injuries.
What could go wrong
This is an early Phase 2 trial with only 120 people, so results may not apply to everyone. The peptide is investigational and its safety and effectiveness are not yet proven.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HAMSTRING MUSCLE STRAIN are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University Shenzhen Hospital
RECRUITINGShenzhen, Guangdong, 518036, China
Contact Phone: •••-•••-•••• Email: •••••@•••••